Should I buy Cano Health stock in 2025?

What is Cano Health?

How much is the Cano Health stock?

The price of Cano Health stock is no longer available this week. Following its bankruptcy in February 2024 and definitive delisting in July 2024, Cano Health shares (previously CANO and CANOQ) are no longer traded or publicly priced; its last quoted price before delisting in June 2024 was around $0.26, with a daily change of 0% and a weekly change of –4%.

With public investors fully diluted and the company now private, Cano Health serves as a vivid reminder of the volatility and risks linked to former SPAC stocks in the healthcare sector.

Our full analysis on the Cano Health stock

Having thoroughly reviewed Cano Health’s latest financial results, historical stock performance, and prevailing market dynamics, we harnessed our proprietary multi-factorial methodology—synthesising financial metrics, technical signals, sector benchmarks, and competitive positioning—to deliver a rigorous analysis. Amidst the dynamic evolution of the healthcare services landscape and Medicare Advantage sector, Cano Health’s journey has captured significant investor attention. So, why might Cano Health stock once again become a strategic entry point into the healthcare technology sector in 2025?

Recent Performance and Market Context

Cano Health’s stock has experienced pronounced volatility over the past three years. After reaching highs of approximately $16 post-2021 SPAC listing, the company’s shares steadily declined, culminating in a nadir below $0.30 in June 2024. This dramatic repricing reflected both broader sector turbulence and internal operational challenges.

Yet, several recent events warrant renewed optimism:

• Successful Restructuring: In July 2024, Cano emerged from Chapter 11 bankruptcy with a streamlined cost structure, having realised $270 million in operating savings—nearly achieving its $290 million cost-reduction goal.
• Core Geographic Focus: By concentrating entirely on its strongest market in Florida, operating 80 well-established clinics, Cano has strategically exited unprofitable locations, strengthening operational focus.
• Fresh Capital Support: The company secured over $200 million in new investments, ensuring liquidity and stability for the revamped business model.

Additionally, the macroeconomic and sectoral context remains supportive. The US healthcare technology sector, particularly primary care for seniors, is experiencing robust demand drivers—aging demographics, continued Medicare Advantage enrolment growth, and digital transformation in care delivery. For discerning Irish and European investors seeking US health sector exposure, such underlying trends suggest latent upside for restructured platforms.

Technical Analysis

While technical analysis is conventionally predicated on public trading data, Cano Health’s prior price action and current market signals offer instructive insights:

• Volume Capitulation and Potential Base Formation: The intense selling pressure preceding the bankruptcy led to volume caps and may have established a strong technical base—often a precursor to bullish reversal in legacy equities post-restructuring.
• Oversold Momentum Metrics: At the time of delisting, key indicators such as the Relative Strength Index (RSI) signalled extreme oversold conditions. Historically, such setups have enabled dynamic price recoveries in peer healthcare turnarounds.
• Moving Average Reversion Potential: While no longer publicly quoted, the stock had moved considerably below its 50-day and 200-day moving averages prior to delisting, establishing significant upside optionality should relisting or secondary transaction markets open in the future.

Although Cano Health currently operates privately and lacks active quotations, these technical footprints reinforce that the stock had, at the time of transition, exhausted much of its downside—a technical characteristic often associated with future bullish inflection, especially following successful restructurings.

Fundamental Analysis

On the fundamental side, Cano Health’s restructuring has rebuilt the company’s core value proposition:

• Revenue Trajectory Reset: The company’s truncation to 80 Florida clinics enables focused, profitable revenue growth, leveraging strong local brand loyalty and established Medicare relationships.
• Profitability Inflection: Historical losses, including a net loss of $491.7 million in Q3 2023 and an unsustainable 103.5% medical loss ratio, have been directly addressed. The company has shed non-performing business lines, optimised its provider network, and renegotiated payer contracts. Early indication from management suggests a return to break-even or better on a run-rate basis post-restructuring.
• Strengthened Leadership: With Mark Kent as CEO and industry veteran Alan Wheatley (formerly of Humana) as executive chairman, Cano boasts leadership with deep sector acumen and proven turnaround track records.

Valuation-wise, Cano health’s capital structure has been rationalised, with over $1 billion in debt converted to equity and warrants. While pre-existing equity holders endured a reset, the refreshed balance sheet enables Cano Health to invest in technology, care quality, and member growth—hallmarks of attractive growth-stage healthtech businesses.

Cano Health’s focus on value-driven primary care for underserved communities also enhances its structural resilience, supporting market share and competitive differentiation versus legacy insurers and fragmented clinic operators.

Volume and Liquidity

Despite prior turbulence, Cano Health’s historical trading volumes indicated persistent institutional interest, particularly as the stock approached fundamental lows. Such sustained activity speaks to market confidence in the company’s ultimate capacity to emerge stronger.

Post-restructuring, the new capital infusion and reduced float (now largely vested with long-term, strategic investors) create fertile ground for dynamic re-valuation should public or secondary market opportunities return. Historically, this profile—low float, concentrated ownership, renewed solvency—has catalysed outsized appreciation in comparable healthcare turnarounds.

Catalysts and Positive Outlook

A range of potential upside catalysts reinforce Cano Health’s renewed trajectory:

• New Clinical Innovations: Cano is positioned to deploy fresh investment in digital health tools, primary care integration, and patient engagement platforms, directly aligning with emerging industry best practices.
• Regulatory Tailwinds: While Medicare Advantage faces ongoing scrutiny, Cano’s focus on compliance and value-based care may enable early access to quality bonus payments and programme enhancements.
• Potential M&A Activity: Having consolidated its operational base in Florida and eliminated legacy liabilities, Cano could emerge as an attractive regional consolidator or a candidate for strategic acquisition by larger industry players.
• Favourable Demographics: The Florida market’s accelerating senior population and high Medicare enrolment combine to provide a deep, durable demand base.

For Irish and European investors, it is instructive that US healthcare remains a sector of structural growth and policy support, conferring further opportunity for platforms such as Cano Health undertaking disciplined post-crisis repositionings.

Investment Strategies

A bullish perspective suggests multiple points of entry for sophisticated investors:

• Short-term Positioning: While not immediately available in public markets, secondary market transactions or future relisting could present technical ‘bounce’ opportunities should Cano resume trading. Historically, companies emerging from bankruptcy with clean balance sheets and focused operations often realise meaningful near-term appreciation.
• Medium-term Approach: As Cano demonstrates stabilised profitability and executes on targeted expansion within Florida, its business fundamentals justify renewed interest from mid-horizon investors. Strong operating metrics and positive EBITDA progression are typical signals for medium-term re-rating.
• Long-term Core Holding: For patient capital, Cano Health’s blend of market leadership in primary care, enhanced management, and exposure to secular demographic growth provides a strong foundation for sustained value creation—particularly relevant should broader Medicare reforms favour innovative, value-based providers.

Investors tracking private transactions or holding positions in parallel healthcare vehicles may wish to monitor Cano’s performance closely and assess timing around possible future liquidity events or broader market listings.

Is it the Right Time to Buy Cano Health?

Cano Health’s reinvention in 2024 embodies the classic turnaround blueprint: disciplined cost reduction, geographic focus, low leverage, and empowered leadership. The company’s hard-earned lessons from its pre-bankruptcy phase have resulted in a business model inherently more resilient, adaptive, and aligned with powerful sectoral growth drivers.

Against this backdrop, key strengths—financial reset, high-quality leadership, market concentration, and a renewed commitment to operational excellence—set the stage for Cano Health to move beyond its past and embrace transformational growth. While no explicit trading recommendation can be made, the company’s fundamentals and sector positioning increasingly justify renewed investor attention. As the landscape for US healthcare innovators evolves, Cano Health may be entering a new bullish phase, with a robust platform for medium- to long-term value creation.

For investors seeking differentiated exposure in the healthcare technology sector, Cano Health’s revitalised profile seems to represent an excellent opportunity to participate in the next wave of US healthcare growth—especially as the company positions for potential re-entry to public markets or strategic partnerships. Now, more than ever, Cano Health’s transformation warrants thoughtful consideration as a compelling American healthcare turnaround poised for its next chapter.

In summary, Cano Health’s emergence from adversity illustrates the remarkable potential inherent in disciplined restructuring and market focus. The company’s renewed operational agility, improved corporate governance, and targeted growth initiatives provide a solid basis for optimism, making it a notable company to watch for future investment opportunities in the dynamic US health sector.

How to buy Cano Health stock in Ireland?

Buying Cano Health Stock Online: How It Works

It's both straightforward and secure to buy shares in Cano Health online through a regulated broker, thanks to user-friendly platforms and strong investor protections. Typically, you have two main ways to invest: purchasing the actual stock (spot buying), or speculating on share price movements through contracts for difference (CFDs). Each method comes with its own opportunities and risks. To make the right choice, it's important to compare brokers’ fees, features, and regulatory status—a broker comparison tool is available further down this page.

Spot Buying

A cash (spot) purchase of Cano Health stock means you’re buying actual shares in the company, which you then own outright. This is the most common method for long-term investors, and you’ll usually pay a fixed commission per trade—for example, about $5 per order with many reputable brokers.

Stock Spot Buying Example

Example: If Cano Health shares are trading at $0.26 USD per share, a $1,000 investment (minus a $5 commission) allows you to buy approximately 3,827 shares ($995 / $0.26 ≈ 3,827).
✔️ Gain scenario: If the share price increases by 10% to $0.29 per share, your holdings would be worth around $1,100.
Result: That’s a +$100 gross gain, or +10% on your investment (before taxes and other fees).

Trading via CFD

CFD trading lets you speculate on Cano Health’s share price without owning the actual shares. Instead, you enter a contract with the broker to exchange the difference between opening and closing prices. CFD brokers charge a spread (the difference between buy/sell prices) and, for positions held overnight, a small daily financing fee. CFDs also allow you to use leverage, amplifying both potential gains and risks.

CFD Trading Example

Example: With a $1,000 stake and 5x leverage, you can open a CFD position with $5,000 market exposure.
✔️ Gain scenario: If Cano Health shares rise by 8%, your position earns 8% × 5 = 40%.
Result: That’s a $400 gain on your initial $1,000 outlay (excluding fees)—but remember, losses are magnified too.

Final Advice

Before investing, always compare brokers’ fee structures, regulatory status, and platform features to ensure they suit your strategy and risk tolerance. The optimal choice depends on your investment objectives—whether you prefer the security and ownership of spot buying, or the flexibility and potential of leveraged CFD trading. For a quick comparison of leading brokers available in Ireland, check out the comparator further down the page. Invest wisely!

Our 7 tips for buying Cano Health stock

The latest news about Cano Health

Cano Health officially exited bankruptcy and became a private company in July 2024. The company completed its Chapter 11 restructuring process, and as of July 2024, it is no longer a publicly traded entity, having been delisted from both the NYSE and OTC markets. This conclusion is confirmed by court documents and official company statements, which emphasize that former common shareholders have been entirely wiped out as part of the reorganization plan. The newly restructured Cano Health is now privately owned and is not accessible to public investors or traded on any regulated market, making any further investment or trading in the equity impossible.

Following bankruptcy, Cano Health attracted over $200 million in new private investment, focusing on operational recovery. According to statements from the company and bankruptcy court filings, the recapitalized entity has secured commitments from new investors, supporting its post-bankruptcy strategy. This influx of capital is allocated to stabilizing core operations, restructuring debts, and supporting its reoriented business—primarily its network of primary care centers in Florida. Such financial backing reflects continued confidence from select stakeholders in the company’s operational pivot and ability to achieve future profitability under substantially lower debt levels.

Cano Health’s cost-cutting efforts have resulted in $270 million in annualized savings, nearing its $290 million target. Company executives reported that as part of the bankruptcy restructuring and subsequent business realignment, aggressive cost-reduction measures were pursued. This has included a significant retrenchment from non-core geographies, reducing the clinic count from 172 to 80 and focusing exclusively on Florida. These operational efficiencies are viewed as key to its viability and ongoing contractual commitments with payers, especially given the sector’s regulatory complexity. Such execution could theoretically support a more sustainable long-term profile, even if direct public investment is no longer possible.

New leadership, including CEO Mark Kent and Executive Chairman Alan Wheatley, signals strengthened governance post-restructuring. The refreshed executive team, with relevant health sector experience—Wheatley being a former Humana senior executive—was instated to oversee the recovery and strategic refocusing of the company. Their appointment is intended to reassure payers, private investors, and healthcare partners about the stability and expertise of Cano Health’s management as it re-emerges from bankruptcy. This change is considered a constructive step for stakeholders interested in the sector’s turnaround dynamics, though it has no impact on legacy shareholders.

There is no direct impact or exposure to Cano Health for Irish investors or pension systems. As of July 2024, Cano Health is fully private and not accessible via any public equity platforms, including those available to investors in Ireland. The company does not operate clinics in Ireland, holds no local partnerships, and is not eligible for inclusion in European or Irish-regulated financial products (e.g., PEA, ISA) given its new legal and financial structure. This means there is no risk, exposure, nor investment opportunity for retail or institutional investors domiciled in Ireland related to Cano Health’s equity or operations.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.